Nanjing Hicin Pharmaceutical: Announcement regarding abnormal fluctuations in stock trading.
Nanjing Hicin Pharmaceutical: Announcement regarding the change of company name and operation scope of a wholly-owned subsidiary.
Nanjing Hicin Pharmaceutical: Announcement on the Progress of Providing Guarantees to Wholly-owned Subsidiaries.
Nanjing Hicin Pharmaceutical: Announcement Regarding the Resignation and Appointment of Deputy General Managers.
Nanjing Hicin Pharmaceutical: Announcement of the resolutions of the 14th meeting of the 4th board of directors.
Nanjing Hicin Pharmaceutical: Announcement of shareholding reduction by shareholders who hold more than 5% of shares to less than 5% and notification of equity changes.
Nanjing Hicin Pharmaceutical: Simplified Equity Change Report
Nanjing Hicin Pharmaceutical: Announcement Regarding Company's Receipt of Approval Notice for Listing Application of Active Pharmaceutical Ingredient
Nanjing Hicin Pharmaceutical: Announcement on the pharmaceutical registration approval of propofol and tenofovir disoproxil fumarate tablets of the company.
Nanjing Hicin Pharmaceutical: Announcement of the implementation of equity distribution in 2023.
Nanjing Hicin Pharmaceutical: Legal Opinion of Jiangsu Century Tongren Law Firm on the Company's 2023 Annual General Meeting of Shareholders
Nanjing Hicin Pharmaceutical: Announcement of Resolutions of the 2023 Annual General Meeting of Shareholders
Nanjing Hicin Pharmaceutical: 2023 Online Results Briefing and Investor Relations Activity Record Form 20240507
Haichen Pharmaceutical: Announcement on renewing the 2024 Audit Institution
Haichen Pharmaceutical: Evaluation Report on the 2023 Performance Status of Accounting Firms
Haichen Pharmaceutical: 2023 Financial Results Report
Haichen Pharmaceutical: 2023 Board Work Report
Haichen Pharmaceutical: 2023 Annual Report Summary
Haichen Pharmaceutical: 2023 Independent Director Debriefing Report (Mao Lingxiao)
Haichen Pharmaceutical: Announcement of Supervisory Board Resolutions
No Data